Dupilumab (Dupixent) was deemed safe for the treatment of atopic dermatitis (AD) in women during pregnancy or breastfeeding, according to data from a meta-analysis published in Acta Dermato-Venereologica.1 However, due to a lack of robust clinical studies included in the analysis, researchers suggested more research is necessary to understand the efficacy and safety of biologics in treating pregnant women with AD.
“AD is the most common skin condition among pregnant women,” wrote authors of the study. “It accounts for around 50% of all dermatoses of pregnancy and usually develops in the second or third trimester.”
During pregnancy, T helper 2 (Th2) responses within the body help women keep their fetus protected, avoiding any risks of spontaneous abortion. But with AD’s prominence among pregnant women, the skin…